<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anastrozole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anastrozole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anastrozole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10953" href="/d/html/10953.html" rel="external">see "Anastrozole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135534"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arimidex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865942"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Anastrozole;</li>
<li>AG-Anastrozole;</li>
<li>APO-Anastrozole;</li>
<li>Arimidex;</li>
<li>BIO-Anastrozole;</li>
<li>CCP-Anastrozole [DSC];</li>
<li>JAMP-Anastrozole;</li>
<li>Mar-Anastrozole;</li>
<li>MINT-Anastrozole;</li>
<li>NAT-Anastrozole;</li>
<li>PMS-Anastrozole;</li>
<li>RIVA-Anastrozole;</li>
<li>SANDOZ Anastrozole;</li>
<li>TARO-Anastrozole;</li>
<li>TEVA-Anastrozole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F135573"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Aromatase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F135538"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70f72d8d-3f95-478a-a281-8d0e7521cd98">Breast cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced:</b> Postmenopausal patients: <b>Oral:</b> 1 mg once daily; continue until tumor progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9233044-fb67-41c4-9005-3558b6ad755e">Breast cancer, advanced, estrogen receptor-positive, HER2-negative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced, estrogen receptor-positive, HER2-negative (off-label combination):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Postmenopausal patients: <b>Oral:</b> 1 mg once daily (in combination with abemaciclib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28968163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28968163'])">Ref</a></span>). Aromatase inhibitors have also been used in combination with palbociclib and ribociclib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959613','lexi-content-ref-29164421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959613','lexi-content-ref-29164421'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenopausal or perimenopausal patients: <b>Oral:</b> 1 mg once daily (in combination with ribociclib [and the luteinizing hormone-releasing hormone (LHRH) agonist goserelin]) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29804902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29804902'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd1dd0d5-ae66-4e94-96b2-6df2016b63d4">Breast cancer, early, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early, adjuvant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Postmenopausal patients: <b>Oral:</b> 1 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Premenopausal patients with high-risk disease (off-label use): <b>Oral: </b>1 mg once daily (in combination with ovarian function suppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337','lexi-content-ref-25403582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337','lexi-content-ref-25403582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> The American Society of Clinical Oncology (ASCO) guidelines for adjuvant endocrine therapy of hormone-receptor positive breast cancer (focused update) recommend a duration of 5 to 10 years of adjuvant endocrine therapy; some patients may be appropriate candidates for extended aromatase inhibitor (AI) therapy for up to a total of 10 years based on disease recurrence risk and nodal disease status. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337'])">Ref</a></span>). In a phase 3 study with another AI (letrozole), treatment with an additional 5 years of AI therapy (for a total of 10 years of AI therapy) demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo), although overall survival was not significantly different between groups and bone-related adverse events occurred more frequently with letrozole versus placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27264120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27264120'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef12445f-5450-4468-80d0-329501655968">Breast cancer in male patients, hormone receptor–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor–positive (off-label use): Note: </b>Should be used in combination with a gonadotropin-releasing hormone agonist/antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant t</i>
<i>herapy (alternative agent):</i> May be used as adjuvant therapy in male patients with hormone receptor–positive breast cancer with a contraindication to tamoxifen. ASCO guidelines for management of male breast cancer recommend an initial duration of 5 years of adjuvant endocrine therapy; if there still is a high risk of recurrence, five additional years of endocrine therapy may be offered if the initial 5 years of adjuvant therapy have been completed and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b> Oral:</b> 1 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23722469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23722469'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d22de8-e4a8-41ee-83bc-1e4e83706316">Breast cancer, risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, risk reduction (off-label use):</b> Postmenopausal patients ≥40 years of age: <b>Oral:</b> 1 mg once daily for 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24333009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24333009'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="620c425d-d61e-44e5-9610-8d8b08995d30">Endometrial or uterine cancer, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial or uterine cancer, recurrent or metastatic (off-label use): Oral:</b> 1 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10926805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10926805'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="479ef10a-6b2a-4e53-99cb-72b1c9e69432">Ovarian cancer, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, recurrent (off-label use): Oral:</b> 1 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675683'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990297"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Kidney impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987599"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment or stable hepatic cirrhosis: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling. However, some sources do not recommend anastrozole use in severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F135539"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54485709"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone mineral density loss/increased fracture risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anastrozole is associated with a <b>decreased bone mineral density </b>(BMD); decreases (from baseline) in total hip BMD (~7% loss after 5 years) and lumbar spine BMD (~6% loss after 5 years) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18309940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18309940'])">Ref</a></span>). Anastrozole has been linked to bone resorption in postmenopausal females; therefore, an increased risk of <b>osteoporosis and bone fracture</b> should be considered when administering treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12404296','lexi-content-ref-18309940','lexi-content-ref-20398352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12404296','lexi-content-ref-18309940','lexi-content-ref-20398352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; anastrozole decreases plasma estrogen levels up to 94% in postmenopausal women with estrogen-positive breast cancer. Low levels of estrogen have been linked to bone resorption leading to decreased BMD, especially at the lumbar spine (LS) and hip. This results in increased risk of osteoporosis and fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12404296','lexi-content-ref-18309940','lexi-content-ref-20398352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12404296','lexi-content-ref-18309940','lexi-content-ref-20398352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; bone loss in LS occurred during the first 2 years of treatment with no additional loss seen in years 2 to 5. No slowing of bone loss occurred in the total hip BMD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18309940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18309940'])">Ref</a></span>). There was a statistically significant LS BMD increase in the 2 years after discontinuing 5 years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20929964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20929964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer durations of aromatase inhibitors (more than 3 years of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21743022','lexi-content-ref-28922781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21743022','lexi-content-ref-28922781'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting known risk factors for BMD loss, osteoporosis, and fracture (includes preexisting osteopenia, age &gt;65 years, years since menopause, body mass index &lt;20 kg/m<sup>2</sup>, personal/family history, chronic glucocorticoid use &gt;6 months, prior fragility fracture history, low bone mineral density, rheumatoid arthritis, and smoking) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18309940','lexi-content-ref-18448451','lexi-content-ref-28413771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18309940','lexi-content-ref-18448451','lexi-content-ref-28413771'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ischemic cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ischemic heart disease</b> has been reported, with an increased incidence of ischemic cardiovascular events in patients with preexisting <b>ischemic heart disease </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18083636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18083636'])">Ref</a></span>). <b>Angina pectoris</b> and <b>acute myocardial infarction</b> (MI) have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; idiosyncratic. Aromatase inhibitors (AIs), such as anastrozole, reduce the protective effects of estrogen, consequently leading to increases in vasoconstriction and atherosclerosis. Additionally, there is a dysregulation of lipid metabolism and potential risk of hyperlipidemia. Together, these factors may increase the risk of cardiovascular disease (CVD) in patients receiving AI for breast cancer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30297439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30297439'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Timing</i>: Varied; cardiac ischemia may occur at any time during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27100398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27100398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting CVD, including ischemic heart disease, or risk factors associated with CVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21743022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21743022'])">Ref</a></span>). In a large SEER-Medicare cohort evaluating MI risk with adjuvant hormone therapy, several preexisting conditions were associated with MI including diabetes with complications, heart failure, prior MI, coronary artery disease, and peripheral vascular disease. In patients with prior history of MI, hazard ratio was nearly 3-fold higher (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30443921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30443921'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer durations of AI therapy (more than 3 years of therapy) are associated with 18% to 26% increased risk of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21743022','lexi-content-ref-30452337','lexi-content-ref-28922781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21743022','lexi-content-ref-30452337','lexi-content-ref-28922781'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Musculoskeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Musculoskeletal effects, including new onset or exacerbation of existing <b>arthralgia</b>, joint stiffness, and/or <b>ostealgia</b>, may occur with anastrozole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478','lexi-content-ref-26598748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478','lexi-content-ref-26598748'])">Ref</a></span>); pain may be severe and/or continuous (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18021478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18021478'])">Ref</a></span>). Aromatase inhibitor-induced arthralgia (AIA) presents with symmetrical joint pains most commonly affecting hands, wrists, and knees (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17761973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17761973'])">Ref</a></span>). Trigger finger and <b>carpal tunnel syndrome</b> may also be common complaints (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23471104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23471104'])">Ref</a></span>). These adverse reactions may significantly affect quality of life and the risk of treatment nonadherence or discontinuation should be considered; treatment discontinuation due to musculoskeletal symptoms has been reported between 5% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, multiple mechanisms have been proposed involving estrogen depletion either as a direct or indirect cause. Proposed estrogen depletion mechanisms include direct local effects on joint tissues, increased inflammatory parameters such as IL-6 indirectly affecting central and peripheral nociception (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16142740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16142740'])">Ref</a></span>), decreased estradiol leading to a decrease in endogenous opioid levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-116723535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-116723535'])">Ref</a></span>), collagen degradation, and impaired regulation of cartilage structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21457526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21457526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; the median time to onset of symptoms is 1.6 to 2 months with a range of 1 week to &gt;10 months. Symptoms have been shown to peak ~6 months after initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17922185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17922185'])">Ref</a></span>). By 18 months, 75% of patients in the ATAC trial had experienced significant improvement of their symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16887480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16887480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior menopausal hormone therapy or previous chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18703382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18703382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Certain CYP19A1 single nucleotide polymorphisms (SNPs) have been associated with increased arthralgia symptoms and/or association with discontinuation of therapy due to intolerable arthralgia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32632513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32632513'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F135504"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (2%; 12% in patients with preexisting ischemic heart disease)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Angina Pectoris table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-angina-pectoris" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-angina-pectoris')">table 1</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Angina Pectoris</span>, hypertension (5% to 13%), ischemic heart disease (4%; increased incidence of ischemic cardiovascular events seen in patients with preexisting ischemic heart disease: 17%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Ischemic Heart Disease table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-ischemic-heart-disease" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-ischemic-heart-disease')">table 2</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Ischemic Heart Disease</span>, vasodilation (25% to 36%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Angina Pectoris" frame="border" id="lexi-content-anastrozole-adverse-reaction-angina-pectoris" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Angina Pectoris</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">216</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">249</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients with preexisting ischemic heart disease</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Ischemic Heart Disease" frame="border" id="lexi-content-anastrozole-adverse-reaction-ischemic-heart-disease" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Ischemic Heart Disease</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">216</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">249</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients with preexisting ischemic heart disease</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (12% to 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal distress (29% to 34%), nausea (11% to 19%), vomiting (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (5% to 13%), fatigue (≤19%), headache (9% to 13%), mood disorder (19%), pain (11% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%; literature suggests incidence as high as 36%) (Howell 2005)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Arthralgia table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-arthralgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-arthralgia')">table 3</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Arthralgia</span>, arthritis (17%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Arthritis table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-arthritis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-arthritis')">table 4</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Arthritis</span>, asthenia (≤19%), back pain (10% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Back Pain table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-back-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-back-pain')">table 5</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Back Pain</span>, ostealgia (7% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Ostealgia table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-ostealgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-ostealgia')">table 6</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Ostealgia</span>, osteoporosis (11%; literature suggests incidence as high as 20% in patients with preexisting osteopenia after 3- to 6-years of anastrazole) (van Hellemond 2019)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Osteoporosis table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-osteoporosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-osteoporosis')">table 7</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Osteoporosis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Arthralgia" frame="border" id="lexi-content-anastrozole-adverse-reaction-arthralgia" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Arthralgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Arthritis" frame="border" id="lexi-content-anastrozole-adverse-reaction-arthritis" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Arthritis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Back Pain" frame="border" id="lexi-content-anastrozole-adverse-reaction-back-pain" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Back Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">511</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Ostealgia" frame="border" id="lexi-content-anastrozole-adverse-reaction-ostealgia" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Ostealgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">511</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Osteoporosis" frame="border" id="lexi-content-anastrozole-adverse-reaction-osteoporosis" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Osteoporosis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (8% to 11%), pharyngitis (6% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (1% in patients with preexisting ischemic heart disease; 0.9%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Acute Myocardial Infarction table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-acute-myocardial-infarction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-acute-myocardial-infarction')">table 8</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Acute Myocardial Infarction</span>, cerebral ischemia (2%), chest pain (5% to 7%), deep vein thrombosis (2%), edema (7%), peripheral edema (5% to 10%), thromboembolic disease (3% to 4%), thrombophlebitis (2% to 5%), venous thrombosis (3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Acute Myocardial Infarction" frame="border" id="lexi-content-anastrozole-adverse-reaction-acute-myocardial-infarction" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Acute Myocardial Infarction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">216</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">249</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">In patients with preexisting ischemic heart disease</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (2% to 5%), diaphoresis (2% to 5%), pruritus (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (9%), increased gamma-glutamyl transferase (2% to 5%), weight gain (2% to 9%), weight loss (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7% to 9%), anorexia (5% to 7%), constipation (7% to 9%), diarrhea (8% to 9%), dyspepsia (7%), gastrointestinal disease (7%), xerostomia (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Leukorrhea (2% to 3%), mastalgia (8%), pelvic pain (5%), urinary tract infection (8%), vaginal discharge (4%), vaginal dryness (2%), vaginal hemorrhage (1% to 5%), vaginitis (4%), vulvovaginitis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4%), leukopenia (2% to 5%), lymphedema (10%), neoplasm (5%), tumor flare (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2% to 5%), increased serum alkaline phosphatase (2% to 5%), increased serum aminotransferase (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (6%), carpal tunnel syndrome (3%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Carpal Tunnel Syndrome table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-carpal-tunnel-syndrome" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-carpal-tunnel-syndrome')">table 9</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Carpal Tunnel Syndrome</span>, confusion (2% to 5%), dizziness (6% to 8%), drowsiness (2% to 5%), hypertonia (3%), insomnia (6% to 10%), lethargy (1%), malaise (2% to 5%), nervousness (2% to 5%), paresthesia (5% to 7%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Carpal Tunnel Syndrome" frame="border" id="lexi-content-anastrozole-adverse-reaction-carpal-tunnel-syndrome" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Carpal Tunnel Syndrome</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (6% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Arthropathy table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-arthropathy" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-arthropathy')">table 10</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Arthropathy</span>, bone fracture (10%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Bone Fracture table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-bone-fracture" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-bone-fracture')">table 11</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Bone Fracture</span>, myalgia (6%)<span class="lexi-table-link-container"> (<a aria-label="Anastrozole: Adverse Reaction: Myalgia table link" class="lexi-table-link" data-table-id="lexi-content-anastrozole-adverse-reaction-myalgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anastrozole-adverse-reaction-myalgia')">table 12</a>)</span><span class="table-link" style="display:none;">Anastrozole: Adverse Reaction: Myalgia</span>, neck pain (2% to 5%), pathological fracture (2% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Arthropathy" frame="border" id="lexi-content-anastrozole-adverse-reaction-arthropathy" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Arthropathy</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described in Arimidex PI 2018.12 as “arthrosis”</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described in Arimidex PI 2018.12 as “joint disorder”</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Bone Fracture" frame="border" id="lexi-content-anastrozole-adverse-reaction-bone-fracture" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Bone Fracture</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anastrozole: Adverse Reaction: Myalgia" frame="border" id="lexi-content-anastrozole-adverse-reaction-myalgia" rules="all">
<caption style="text-align:center;">
<b>Anastrozole: Adverse Reaction: Myalgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Tamoxifen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Anastrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tamoxifen)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,092</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,094</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (5%), dyspnea (8% to 10%), flu-like symptoms (6% to 7%), rhinitis (2% to 5%), sinusitis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (10%), cyst (5%), fever (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer, skin blister</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Endometrial carcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatitis, hepatomegaly, jaundice</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Cerebral infarction (Sagara 2010), pulmonary embolism (Lycette 2006), retinal thrombosis (Eisner 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (Kim 2020), dermatologic disorder (lichen sclerosus) (Agrawal 2017; Potter 2013), erythema multiforme (Cozzani 2018; Wollina 2018), hypersensitivity angiitis (Shoda 2005), pruritic rash (Bremec 2009; Tanaka 2019), Stevens-Johnson syndrome, urticaria (Bock 2014), xeroderma (Cristofanilli 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Järhult 2014; Yu 2016), hyperparathyroidism (Järhult 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Polycythemia (Kapoor 2019; Yeruva 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin, liver steatosis (Lacey 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Pulmonary cryptococcosis (Wei 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tardive dyskinesia (Manjunatha 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (common: ≥10%) (Eastell 2008; Markopoulos 2010), subacute cutaneous lupus erythematosus (Fisher 2016), tendinopathy (Martens 2007), tenosynovitis (stenosing)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Vitreous traction (Eisner 2008)</p></div>
<div class="block coi drugH1Div" id="F135516"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to anastrozole or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy, breastfeeding.</p></div>
<div class="block war drugH1Div" id="F135501"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Plasma concentrations in patients with stable hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials.</p></div>
<div class="block foc drugH1Div" id="F135511"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arimidex: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg</p></div>
<div class="block geq drugH1Div" id="F135497"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F135518"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Anastrozole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $6.94 - $13.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Arimidex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $65.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865943"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arimidex: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg</p></div>
<div class="block adm drugH1Div" id="F6884236"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food.</p></div>
<div class="block hazard drugH1Div" id="F49104430"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F135512"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment of locally advanced or metastatic breast cancer (hormone receptor–positive or unknown) in postmenopausal patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of advanced breast cancer in postmenopausal patients with disease progression following tamoxifen therapy.</p></div>
<div class="block off-label drugH1Div" id="F25721921"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, high-risk, hormone receptor–positive, adjuvant endocrine therapy in premenopausal patients (in combination with ovarian function suppression); Breast cancer in male patients, hormone receptor–positive; Endometrial or uterine cancers (recurrent or metastatic); Ovarian cancer (recurrent); Risk reduction for breast cancer in postmenopausal patients</p></div>
<div class="block mst drugH1Div" id="F6743663"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anastrozole may be confused with anagrelide, letrozole</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arimidex may be confused with Aromasin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F135567"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F135506"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Anastrozole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Aromatase Inhibitors may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: May decrease the serum concentration of Anastrozole.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52576602"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to therapy. Verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for at least 3 weeks after the last anastrozole dose.</p></div>
<div class="block pri drugH1Div" id="F135519"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, anastrozole may cause fetal harm if exposure occurs during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F20543963"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if anastrozole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for 2 weeks after the last anastrozole dose.</p></div>
<div class="block mop drugH1Div" id="F1878921"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hormone-receptor status. Bone mineral density at baseline and periodically thereafter; total cholesterol and LDL. Pregnancy test (prior to treatment in patients who could become pregnant). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast cancer risk reduction (off-label use): Bone mineral density at baseline, mammograms, and clinical breast exam at baseline and at least every 2 years (Cuzick 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring for patients with breast cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually in patients with a high 10-year risk (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F135500"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Anastrozole is a potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels.</p></div>
<div class="block phk drugH1Div" id="F135515"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of estradiol reduction: 70% reduction after 24 hours; 80% after 2 weeks of therapy</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of estradiol reduction: 6 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed; extent of absorption not affected by food</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: 40% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic (~85%) via N-dealkylation, hydroxylation, and glucuronidation; primary metabolite (triazole) inactive </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~50 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~2 hours without food; 5 hours with food </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces; urine (urinary excretion accounts for ~10% of total elimination, mostly as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51220438"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Renal clearance is decreased proportionally with CrCl and was approximately 50% lower in those with severe renal function impairment (CrCl less than 30 mL/minute per 1.73 m<sup>2</sup>); this reduced total body clearance by 10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Oral clearance was approximately 30% lower in those with stable hepatic cirrhosis, but plasma concentrations were within normal range.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135520"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arimidex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anastradex | Anastrazol rontag | Anastrozol glenmark | Anastrozol gp pharm | Anastrozol Kilab | Anebol | Arimidex | Cefer | Leprofen | Pantestone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Anastro | Anastrolan | Anastrozol +pharma | Anastrozol 1 A Pharma | Anastrozol actavis | Anastrozol arcana | Anastrozol bluefish | Anastrozol genericon | Anastrozol Hikma | Anastrozol kabi | Anastrozol medico uno | Anastrozol Ranbaxy | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Arimidex | Nastrin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anastrol | Anastrozole an | Anastrozole drla | Anastrozole fbm | Anastrozole ga | Anastrozole lw | Anastrozole ps | Anastrozole rbx | Anastrozole sandoz | Anastrozole synthon | Anzole | Apo anastrozole | Arianna | Arimidex | Astzol | Azastrole | Pharmacor anastrozole | Stada anastrozole | Terry white chemists anastrozole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arimidex | Aromatin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Anastrarom | Anastrozol actavis | Anastrozol Apotex | Anastrozol sandoz | Anastrozole Accord | Anastrozole EG | Anastrozole Mylan | Anastrozole teva | Arimidex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Anastrazole denk | Anatero | Arimidex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Anaromat | Anastrocon | Anastrogratis | Anastrozex | Arimidex | Armotraz | Kyaresta | Zenbrest</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Anastrolibbs | Anastrozol | Anya | Arazabi | Arimidex | Trozolet</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol actavis | Anastrozol devatis | Anastrozol Helvepharm | Anastrozol Mepha | Anastrozol Orion | Anastrozol sandoz | Anastrozol teva | Anastrozol zentiva | Arimidex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole denk | Anatero | Arimidex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol | Anasvitae | Arimidex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai da | Arimidex | Rui si yi | Rui ting</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aizol | Anana | Anastole | Anastrozol | Anastrozol denk | Armistraz | Hb oncocare | Prazolar | Trozolet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alozex | Anaprex | Anastar | Anastrad | Anastrozol | Anastrozol +pharma | Anastrozol actavis | Anastrozol Medac | Anastrozol Mylan | Anastrozol sandoz | Anastrozole grindeks | Anastrozole Medico Uno | Anastrozole Pharmacenter | Anastrozole teva | Anaya | Apo anastrozol | Arimidex | Asnea | Atrocela | Egistrozol | Mastoren | Oncofem | Zenbrest | Zynzol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anablock | Anadex | Anastro Cell | Anastrohexal | Anastromin | Anastropuren | Anastrozol | Anastrozol 1 A Pharma | Anastrozol Accord | Anastrozol acino | Anastrozol Acis | Anastrozol actavis | Anastrozol AL | Anastrozol amarox | Anastrozol aristo | Anastrozol Atid | Anastrozol axcount | Anastrozol Axios | Anastrozol Basic | Anastrozol Beta | Anastrozol biomo | Anastrozol bluefish | Anastrozol CT | Anastrozol denk | Anastrozol devatis | Anastrozol dura | Anastrozol Fair Med | Anastrozol glenmark | Anastrozol Heumann | Anastrozol Hormosan | Anastrozol kabi | Anastrozol Medicom | Anastrozol onkovis | Anastrozol Pfizer | Anastrozol Q | Anastrozol ratiopharm | Anastrozol Stada | Anastrozol Sun | Anastrozol teva | Anastrozol Winthrop | Arimidex | Eurostrozol | Ribomidex</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amtraz | Anebol | Antrozol | Armotraz</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol | Anasvitae | Anatero | Arimidex | Trozolet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol ratiopharm | Anastrozole Accord | Anastrozole actavis | Anastrozole sandoz | Anastrozole Swiss | Anastrozole teva | Arimidex | Axastrol | Mammozole | Zynzol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anastrodex | Anastrozol sandoz | Anastrozol Synthon | Anastrozole pharmacare | Arimidex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amenur | Anabrest | Anastrozol Accord | Anastrozol actavis | Anastrozol Apotex | Anastrozol aristo | Anastrozol bluefish | Anastrozol Cinfa | Anastrozol Combix | Anastrozol curaxys | Anastrozol Davur | Anastrozol Kern pharma | Anastrozol Mabo | Anastrozol Normon | Anastrozol Pensa | Anastrozol Pharmagenus | Anastrozol Ranbaxy | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozol Tarbis | Anastrozol teva | Anastrozol UR | Anastrozol Vegal | Anastrozol Winthrop | Arimidex | Curmyl</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Anastronat | Anastrozol sandoz | Anastrozole denk | Aremed | Arimidex | Womazole</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Anastelb | Anastrozol actavis | Anastrozol eql pharma | Anastrozol Medac | Anastrozol Mylan | Anastrozol Orifarm | Anastrozol Orion | Anastrozol Pensa | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozol teva | Anastrozole bluefish | Anazol | Arimidex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole Accord | Anastrozole Almus | Anastrozole Alter | Anastrozole Arrow | Anastrozole biogaran | Anastrozole bluefish | Anastrozole cristers | Anastrozole EG | Anastrozole evolugen | Anastrozole gerda | Anastrozole Isomed | Anastrozole Mylan | Anastrozole Phr | Anastrozole ranbaxy | Anastrozole ratiopharm | Anastrozole sandoz | Anastrozole teva | Anastrozole Winthrop | Anastrozole Zydus | Arimidex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arimidex | Nastrosa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anastrogen | Anastrozole teva | Anastrozole/Generics | Arimidex | Astrazol | Avomin | Enastros | Londer | Oxeda | Viastrol | Zolitrat</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aremed | Arimidex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Anastris | Anastrozol JGL | Anastrozol Pliva | Anastrozol sandoz | Aremed | Arimidex | Armotraz | Astralis | Azonet | Strazolan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Anamataz | Anaromat | Anastrozol +pharma | Anastrozol kabi | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozole bluefish | Anastrozole medine | Anastrozole Pharmacenter | Arilla | Arimidex | Atrocela | Axastrol | Mammozole | Mastoren | Nobrec | Valmidex | Zynzol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anamidex | Arimidex | Bracer</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Agerdex | Amidex | Anastrozole actavis | Anastrozole bluefish | Anastrozole Niche | Anastrozole teva | Arimidex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Arimidex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adova | Altraz | Anabrez | Anaday | Anamit | Anastronat | Anastroz | Anazol | Anosam | Arimidex | Armotraz | Aromita | Avantaz | Elinal | Femistra | Lilmantro | Oncozole | Qubol | Stazonex | Trazocad | Xenosoul</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adiunastrol | Anastrozolo | Anastrozolo accord healthcare | Anastrozolo actavis | Anastrozolo alter | Anastrozolo Bluefish | Anastrozolo doc generici | Anastrozolo mylan generics | Anastrozolo professionalcare | Anastrozolo sandoz | Anastrozolo Sun | Anastrozolo teva | Anastrozolo Winthrop | Arimidex | Extroplex | Ibistrazolo | Iniben | Keyfen | Renazole</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Anarix | Aremed | Arimidex | Armotraz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole sn | Arimidex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anastrazole denk | Anatero | Arimidex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A Dex | Anarozol | Anasprin | Anasto | Arimidex | Arimista | Atrozole | Femizet | Teva anastrozole</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo anastrozole | Arimidex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anastrazol vegal | Anastrozole biogaran | Anastrozole bluefish | Apo anastrozole | Arimidex | Victeve | Zortex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol actavis | Anastrozol ratiopharm | Anastrozole Accord | Anastrozole actiopharma | Anastrozole elvim | Anastrozole orion | Anastrozole sandoz | Anastrozole Sanoswiss | Anastrozole teva | Arimidex | Axastrol | Egistrozol | Mammozole | Zynzol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol ratiopharm | Anastrozol sandoz | Anastrozole EG | Arimidex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anastera | Anastrozole Accord | Anastrozole actavis | Anastrozole orion | Anastrozole sandoz | Anastrozole Sanoswiss | Anastrozole teva | Arimidex | Axastrol | Mammozole | Zenbrest | Zynzol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole zenith | Arimidex | Aritrozole</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acetraz | Anasa | Anastrozol | Anastrozol Synthon | Anna | Arimidex | Asoinacor | Breazoc | Deramedra | Femistra | Femizet | Lapostim | Magemiv | Naztegan | Orminib | Poscirol | Probitor | Quifamider | Tamcevan | Treure | Ultrodena | Wisbulon | Zolasatin | Zurozol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anast | Ansuzole | Aremed | Arimidex | Armotraz | Dp anastrozole | Femizet</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol | Anastrozol Accord | Anastrozol actavis | Anastrozol Apotex | Anastrozol bluefish | Anastrozol cf | Anastrozol focus | Anastrozol Mylan | Anastrozol pch | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Sun | Anastrozol Synthon | Arimidex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol bluefish | Anastrozol Medac | Anastrozol medical valley | Anastrozol sandoz | Anastrozole teva | Arimidex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Anatrole | Aremed | Arimidex | Dp anastrozole | Rolin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol | Arimidex | Astrol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anarom | Anastrozole Biomedis | Anatero | Anazole | Andrazole | Anzol | Aremed 1 | Arimidex | Armida | Sananas | Scitrozole | Strazol | Vexal A</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adnast | Anabrec | Anastrozole belmed | Anastrozole sandoz | Anazole | Arimidex | Arimisol | Astrolex | Atzol | Femizet | Geneplex | Nastozol | Pantestone | Redest</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anastralan | Anastrolek | Anastrozol Medac | Anastrozol ratiopharm | Anastrozol teva | Anastrozole Accord | Anastrozole Arrow | Anastrozole bluefish | Anastrozole orion | Apo nastrol | Arimidex | Atrozol | Egistrozol | Symanastrol | Zolastrol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Arimidex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol | Anastrozol Accord | Anastrozol actavis | Anastrozol farmoz | Anastrozol germed | Anastrozol Hikma | Anastrozol kabi | Anastrozol Mylan | Anastrozol Stada | Arimidex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol imedic | Anastrozol richmond | Arimidex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Anastralex | Arimidex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anaromat | Anastraze | Anastrozol atb | Anastrozol bluefish | Anastrozol kabi | Anastrozol terapia | Anastrozol teva | Anastrozole Medico Uno | Arimidex | Egistrozol | Eloza | Enzamidex | Kyaresta | Ozolan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Anabrez | Anastera | Anastrex | Anastrosol Kabi | Anastrozole kabi | Anastrozole teva | Anastrozole tl | Anazales | Arimidex | Axastrol | Egistrazole | Estarizol | Mammosole | Selana | Vero Anastrosol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Arimidex | Tabidex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Anastelb | Anastrozol abacus medicine | Anastrozol actavis | Anastrozol Arrow | Anastrozol Campus | Anastrozol ebb | Anastrozol eql pharma | Anastrozol Medac | Anastrozol medical valley | Anastrozol Mylan | Anastrozol Orifarm | Anastrozol Pensa | Anastrozol sandoz | Anastrozole 2care4 | Anastrozole Accord | Anastrozole bluefish | Anastrozole mds | Anastrozole teva | Arimidex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Arimidex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anastrozol lek | Anastrozol teva | Arimidex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anaprex | Anastelb | Anastrozol +pharma | Anastrozol ebewe | Anastrozol sandoz | Anastrozole bluefish | Anastrozole grindeks | Anastrozole Medico Uno | Anastrozole Pharmacenter | Arimidex | Asnea | Ozolan | Zenbrest</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole sandoz | Aremed | Arimidex | Femizet</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anastra | Anastrodex | Anastrozole zentiva | Avomin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anazol | Arimidex | Aristu | Santra | Veridex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anazo | Anotrole | Aremed | Arimidex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Actastrozol | Anastera | Anastrozol sandoz | Anastrozol vista | Anatero | Arimidex | Axastrol | Egistrozol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole denk | Anatero | Arimidex | Womazole</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Anastrol | Anastrozol | Arimidex | Pantestone | Trozolet</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anastwin | Arimidex | Trozolet</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aritrodex | Asstrozol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord anastrozole | Anabrez | Anastrozole sandoz | Arimidex | Castra | Everdex | Mylan Anastrozole | Stradexa | Teva anastrozole</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Anastrozole denk | Anatero | Arimidex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Anatero | Arimidex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agrawal.2017">
<a name="Agrawal.2017"></a>Agrawal C, Pradeep Babu KV, Dash PK, Saini R. Oral lichen sclerosus in a breast cancer patient on anastrozole therapy: a case report with brief review of literature. <i>Arch Med Health Sci.</i> 2017;5:245‑247.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21743022">
<a name="21743022"></a>Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. <i>J Natl Cancer Inst</i>. 2011;103(17):1299-1309. doi:10.1093/jnci/djr242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/21743022/pubmed" id="21743022" target="_blank">21743022</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Arimidex (anastrozole) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arimidex.2">
<a name="Arimidex.2"></a>Arimidex (anastrozole) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24575835">
<a name="24575835"></a>Bock VL, Friedlander M, Waring D, Kossard S, Wood GK. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. <i>Australas J Dermatol</i>. 2014;55(4):282-285. doi:10.1111/ajd.12110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/24575835/pubmed" id="24575835" target="_blank">24575835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32632513">
<a name="32632513"></a>Borrie AE, Rose FA, Choi YH, et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. <i>Breast Cancer Res Treat</i>. 2020;183(2):365-372. doi:10.1007/s10549-020-05777-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/32632513/pubmed" id="32632513" target="_blank">32632513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19903442">
<a name="19903442"></a>Bremec T, Demsar J, Luzar B, Pavlović MD. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor. <i>Dermatol Online J</i>. 2009;15(7):14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19903442/pubmed" id="19903442" target="_blank">19903442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol</i>. 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline update on ovarian suppression. <i>J Clin Oncol.</i> 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16887480">
<a name="16887480"></a>Buzdar A, Howell A, Cuzick J, et al; Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncol</i>. 2006;7(8):633-643. doi:10.1016/S1470-2045(06)70767-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16887480/pubmed" id="16887480" target="_blank">16887480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12404296">
<a name="12404296"></a>Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. <i>Cancer</i>. 2002;95(9):2006-2016. doi: 10.1002/cncr.10908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12404296/pubmed" id="12404296" target="_blank">12404296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29668491">
<a name="29668491"></a>Cozzani E, Trave I, Burlando M, Parodi A. Erythematous maculopapular eruption induced by anastrozole: the first case. <i>Am J Ther</i>. 2018;25(6):e743-e744. doi:10.1097/MJT.0000000000000755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/29668491/pubmed" id="29668491" target="_blank">29668491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761973">
<a name="17761973"></a>Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. <i>J Clin Oncol</i>. 2007;25(25):3877-3883. doi:10.1200/JCO.2007.10.7573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/17761973/pubmed" id="17761973" target="_blank">17761973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20215537">
<a name="20215537"></a>Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>Clin Cancer Res</i>. 2010;16(6):1904-1914. doi:10.1158/1078-0432.CCR-09-2282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/20215537/pubmed" id="20215537" target="_blank">20215537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24333009">
<a name="24333009"></a>Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i>. 2014;383(9922):1041-1048. doi: 10.1016/S0140-6736(13)62292-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/24333009/pubmed" id="24333009" target="_blank">24333009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675683">
<a name="14675683"></a>del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. <i>Gynecol Oncol</i>. 2003;91(3):596-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/14675683/pubmed" id="14675683" target="_blank">14675683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35123662">
<a name="35123662"></a>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncol</i>. 2022;23(3):382-392. doi:10.1016/S1470-2045(21)00758-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/35123662/pubmed" id="35123662" target="_blank">35123662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20929964">
<a name="20929964"></a>Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Ann Oncol</i>. 2011;22(4):857-862. doi:10.1093/annonc/mdq541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/20929964/pubmed" id="20929964" target="_blank">20929964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18309940">
<a name="18309940"></a>Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. <i>J Clin Oncol</i>. 2008;26(7):1051-1057. doi: 10.1200/JCO.2007.11.0726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18309940/pubmed" id="18309940" target="_blank">18309940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18451730">
<a name="18451730"></a>Eisner A, Falardeau J, Toomey MD, Vetto JT. Retinal hemorrhages in anastrozole users. <i>Optom Vis Sci</i>. 2008;85(5):301-308. doi:10.1097/OPX.0b013e31816bea3b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18451730/pubmed" id="18451730" target="_blank">18451730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16142740">
<a name="16142740"></a>Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. <i>Arthritis Rheum</i>. 2005;52(9):2594-2598. doi:10.1002/art.21364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16142740/pubmed" id="16142740" target="_blank">16142740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959613">
<a name="27959613"></a>Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. <i>N Engl J Med.</i> 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27959613/pubmed" id="27959613" target="_blank">27959613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27622265">
<a name="27622265"></a>Fisher J, Patel M, Miller M, Burris K. Anastrozole-induced subacute cutaneous lupus erythematosus. <i>Cutis</i>. 2016;98(2):E22–E26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27622265/pubmed" id="27622265" target="_blank">27622265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18083636">
<a name="18083636"></a>Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncol</i>. 2008;9(1):45-53. doi: 10.1016/S1470-2045(07)70385-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18083636/pubmed" id="18083636" target="_blank">18083636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21457526">
<a name="21457526"></a>Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. <i>Breast Cancer Res</i>. 2011;13(2):205. doi:10.1186/bcr2818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/21457526/pubmed" id="21457526" target="_blank">21457526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25403582">
<a name="25403582"></a>Gnant M, Mlineritsch B, Stoeger H, et al; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Ann Oncol</i>. 2015;26(2):313-320. doi:10.1093/annonc/mdu544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/25403582/pubmed" id="25403582" target="_blank">25403582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28968163">
<a name="28968163"></a>Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer.<i> J Clin Oncol.</i> 2017;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/28968163/pubmed" id="28968163" target="_blank">28968163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28922781">
<a name="28922781"></a>Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. <i>J Natl Cancer Inst</i>. 2018;110(1):10.1093/jnci/djx141. doi:10.1093/jnci/djx141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/28922781/pubmed" id="28922781" target="_blank">28922781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27264120">
<a name="27264120"></a>Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. <i>N Engl J Med</i>. 2016;375(3):209-219. doi: 10.1056/NEJMoa1604700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27264120/pubmed" id="27264120" target="_blank">27264120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28413771">
<a name="28413771"></a>Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. <i>J Bone Oncol</i>. 2017;7:1-12. doi:10.1016/j.jbo.2017.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/28413771/pubmed" id="28413771" target="_blank">28413771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18448451">
<a name="18448451"></a>Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. <i>Ann Oncol</i>. 2008;19(8):1407-1416. doi:10.1093/annonc/mdn164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18448451/pubmed" id="18448451" target="_blank">18448451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27100398">
<a name="27100398"></a>Haque R, Shi J, Schottinger JE, et al. Cardiovascular disease after aromatase inhibitor use. <i>JAMA Oncol</i>. 2016;2(12):1590-1597. doi:10.1001/jamaoncol.2016.0429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27100398/pubmed" id="27100398" target="_blank">27100398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17922185">
<a name="17922185"></a>Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <i>Breast Cancer Res Treat</i>. 2008;111(2):365-372. doi:10.1007/s10549-007-9774-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/17922185/pubmed" id="17922185" target="_blank">17922185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15639680">
<a name="15639680"></a>Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet</i>. 2005;365(9453):60-62. doi:10.1016/S0140-6736(04)17666-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/15639680/pubmed" id="15639680" target="_blank">15639680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21290264">
<a name="21290264"></a>Järhult J. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. <i>Breast Cancer</i>. 2014;21(3):379-381. doi:10.1007/s12282-011-0253-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/21290264/pubmed" id="21290264" target="_blank">21290264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18768369">
<a name="18768369"></a>Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncol</i>. 2008;9(10):953-961. doi: 10.1016/S1470-2045(08)70207-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18768369/pubmed" id="18768369" target="_blank">18768369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30443921">
<a name="30443921"></a>Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. <i>Clin Cardiol</i>. 2019;42(1):93-100. doi:10.1002/clc.23114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30443921/pubmed" id="30443921" target="_blank">30443921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30828176">
<a name="30828176"></a>Kapoor J, Singh N, Agrawal N, Ahmed R, Bhurani D. A case of anastrozole-induced erythrocytosis. <i>Indian J Hematol Blood Transfus</i>. 2019;35(1):194-195. doi:10.1007/s12288-018-1022-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30828176/pubmed" id="30828176" target="_blank">30828176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17563395">
<a name="17563395"></a>Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. <i>J Clin Oncol</i>. 2007;25(19):2664-2670. doi: 10.1200/JCO.2006.08.8054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/17563395/pubmed" id="17563395" target="_blank">17563395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16443612">
<a name="16443612"></a>Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. <i>Ann Oncol</i>. 2006;17(4):584-587. doi: 10.1093/annonc/mdj127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16443612/pubmed" id="16443612" target="_blank">16443612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31965545">
<a name="31965545"></a>Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adversee Events. <i>Dermatol Ther (Heidelb)</i>. 2020;10(1):221-229. doi:10.1007/s13555-020-00353-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/31965545/pubmed" id="31965545" target="_blank">31965545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12113022">
<a name="12113022"></a>Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. <i>Expert Rev Anticancer Ther</i>. 2001;1(2):169-176. doi:10.1586/14737140.1.2.169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12113022/pubmed" id="12113022" target="_blank">12113022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25540208">
<a name="25540208"></a>Lacey R, Evans A. An unusual cause of jaundice in a patient with breast cancer. <i>BMJ Case Rep</i>. 2014;2014:bcr2014205764. doi:10.1136/bcr-2014-205764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/25540208/pubmed" id="25540208" target="_blank">25540208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9797018">
<a name="9797018"></a>Lønning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. <i>Breast Cancer Res Treat</i>. 1998;49(suppl 1):S53-S57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/9797018/pubmed" id="9797018" target="_blank">9797018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14513434">
<a name="14513434"></a>Lønning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. <i>Semin Oncol</i>. 2003;30(4)(suppl 14):23-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/14513434/pubmed" id="14513434" target="_blank">14513434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16752073">
<a name="16752073"></a>Lycette JL, Luoh SW, Beer TM, Deloughery TG. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature. <i>Breast Cancer Res Treat</i>. 2006;99(3):249-255. doi:10.1007/s10549-006-9212-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16752073/pubmed" id="16752073" target="_blank">16752073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24026733">
<a name="24026733"></a>Manjunatha N, Ganjekar S, Mahendra JV, Kilara N, Srinivasa R. Tardive dyskinesia associated with anastrozole. <i>J Neuropsychiatry Clin Neurosci</i>. 2013;25(3):E27-E28. doi:10.1176/appi.neuropsych.12060159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/24026733/pubmed" id="24026733" target="_blank">24026733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20398352">
<a name="20398352"></a>Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. <i>Breast Cancer Res</i>. 2010;12(2):R24. doi:10.1186/bcr2565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/20398352/pubmed" id="20398352" target="_blank">20398352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17726034">
<a name="17726034"></a>Martens HA, Schröder CP, van der Eerden PJ, Willemse PH, Posthumus MD. Severe disabling tendinopathy caused by anastrazole. <i>Rheumatology (Oxford)</i>. 2007;46(10):1619-1621. doi:10.1093/rheumatology/kem213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/17726034/pubmed" id="17726034" target="_blank">17726034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30297439">
<a name="30297439"></a>Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. <i>BMJ</i>. 2018;363:k3845. doi:10.1136/bmj.k3845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30297439/pubmed" id="30297439" target="_blank">30297439</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC; 2014. http://nof.org/files/nof/public/content/file/2791/upload/919.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23471104">
<a name="23471104"></a>Niravath P. Aromatase inhibitor-induced arthralgia: a review. <i>Ann Oncol</i>. 2013;24(6):1443-1449. doi:10.1093/annonc/mdt037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/23471104/pubmed" id="23471104" target="_blank">23471104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473018">
<a name="10473018"></a>Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. <i>Drugs</i>. 1999;58(2):233-255. doi: 10.2165/00003495-199958020-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/10473018/pubmed" id="10473018" target="_blank">10473018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19932916">
<a name="19932916"></a>O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. <i>Gynecol Oncol.</i> 2010;116(3):424-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19932916/pubmed" id="19932916" target="_blank">19932916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29164421">
<a name="29164421"></a>O'Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Res Treat</i>. 2018;168(1):127-134. doi:10.1007/s10549-017-4518-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/29164421/pubmed" id="29164421" target="_blank">29164421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22956445">
<a name="22956445"></a>Potter JE, Moore KA. Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report. <i>J Gen Intern Med</i>. 2013;28(4):592-595. doi:10.1007/s11606-012-2209-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/22956445/pubmed" id="22956445" target="_blank">22956445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18021478">
<a name="18021478"></a>Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. <i>Clin Breast Cancer</i>. 2007;7(10):775-778. doi:10.3816/CBC.2007.n.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18021478/pubmed" id="18021478" target="_blank">18021478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19914530">
<a name="19914530"></a>Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. <i>Breast</i>. 2009;18(suppl 3):S122-S130. doi: 10.1016/S0960-9776(09)70286-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19914530/pubmed" id="19914530" target="_blank">19914530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10926805">
<a name="10926805"></a>Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. <i>Gynecol Oncol</i>. 2000;78(2):212-216. doi: 10.1006/gyno.2000.5865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/10926805/pubmed" id="10926805" target="_blank">10926805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19526308">
<a name="19526308"></a>Sagara Y, Kosha S, Baba S, et al. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. <i>Breast Cancer</i>. 2010;17(3):212-217. doi:10.1007/s12282-009-0135-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19526308/pubmed" id="19526308" target="_blank">19526308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18703382">
<a name="18703382"></a>Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. <i>Lancet Oncol</i>. 2008;9(9):866-872. doi:10.1016/S1470-2045(08)70182-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/18703382/pubmed" id="18703382" target="_blank">18703382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19752338">
<a name="19752338"></a>Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. <i>J Clin Oncol</i>. 2009;27(30):4961-4965. doi:10.1200/JCO.2009.22.0236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/19752338/pubmed" id="19752338" target="_blank">19752338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15769928">
<a name="15769928"></a>Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. <i>Ann Rheum Dis</i>. 2005;64(4):651-652. doi:10.1136/ard.2004.023150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/15769928/pubmed" id="15769928" target="_blank">15769928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-116723535">
<a name="116723535"></a>Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. <i>J Neurosci</i>. 2006;26(21):5777-5785. doi:10.1523/JNEUROSCI.5223-05.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/16723535/pubmed" id="16723535" target="_blank">16723535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598748">
<a name="26598748"></a>Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial. <i>J Clin Oncol</i>. 2016;34(2):139-143. doi:10.1200/JCO.2015.63.4972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/26598748/pubmed" id="26598748" target="_blank">26598748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31011314">
<a name="31011314"></a>Tanaka A, Yamashita C, Hinogami H, Shirai H, Yamamura J, Ito R. Localized cutaneous adverse event induced by anastrozole as adjuvant treatment for breast cancer: a case report. <i>Case Rep Dermatol</i>. 2019;11(1):57-63. doi:10.1159/000497469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/31011314/pubmed" id="31011314" target="_blank">31011314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12485966">
<a name="12485966"></a>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. <i>Circulation</i>. 2002;106(25):3143-3421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/12485966/pubmed" id="12485966" target="_blank">12485966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29804902">
<a name="29804902"></a>Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncol</i>. 2018;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/29804902/pubmed" id="29804902" target="_blank">29804902</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 31, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30748011">
<a name="30748011"></a>van Hellemond IEG, Smorenburg CH, Peer PGM, et al. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>Int J Cancer</i>. 2019;145(5):1325-1333. doi:10.1002/ijc.32205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/30748011/pubmed" id="30748011" target="_blank">30748011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479306">
<a name="31479306"></a>Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. <i>J Clin Oncol.</i> 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/31479306/pubmed" id="31479306" target="_blank">31479306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31914067">
<a name="31914067"></a>Wei M, Xu YR, Liu K, Wen P. Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: a case report. <i>Medicine (Baltimore)</i>. 2020;99(2):e18688. doi:10.1097/MD.0000000000018688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/31914067/pubmed" id="31914067" target="_blank">31914067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483990">
<a name="29483990"></a>Wollina U, Schönlebe J, Heinig B, Tchernev G, França K, Lotti T. Segmental erythema multiforme-like drug eruption by aromatase inhibitor anastrozole - first case report and another example of an immunocompromised district. <i>Open Access Maced J Med Sci</i>. 2018;6(1):79-81. doi:10.3889/oamjms.2018.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/29483990/pubmed" id="29483990" target="_blank">29483990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26137331">
<a name="26137331"></a>Yeruva SL, Nwabudike SM, Ogbonna OH, Oneal P. Aromatase inhibitor-induced erythrocytosis in a patient undergoing hormonal treatment for breast cancer. <i>Case Rep Hematol</i>. 2015;2015:784783. doi:10.1155/2015/784783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/26137331/pubmed" id="26137331" target="_blank">26137331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27369187">
<a name="27369187"></a>Yu R. Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism. <i>Endocrine</i>. 2016;53(3):868-869. doi:10.1007/s12020-016-1006-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/27369187/pubmed" id="27369187" target="_blank">27369187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25850534">
<a name="25850534"></a>Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis. <i>Breast Cancer Res Treat</i>. 2015;151(1):141-147. doi:10.1007/s10549-015-3356-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/25850534/pubmed" id="25850534" target="_blank">25850534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23722469">
<a name="23722469"></a>Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series.<i> Br J Cancer</i>. 2013;108(11):2259-2263. doi:10.1038/bjc.2013.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anastrozole-drug-information/abstract-text/23722469/pubmed" id="23722469" target="_blank">23722469</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8780 Version 344.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
